Beta Bionics Outlines Automation-Focused Insulin Delivery Strategy

Company highlights iLet pump's automated features, pharmacy reimbursement, and commercial expansion plans

Published on Mar. 6, 2026

Got story updates? Submit your updates here. ›

Beta Bionics, a medical device company focused on automated insulin delivery, used a recent conference presentation to outline its growth strategy. Key elements include positioning the iLet insulin pump as an 'automation-forward' system that reduces setup and management burden for healthcare providers, expanding its commercial footprint, and developing a new patch pump called Mint. The company also discussed progress on a bi-hormonal pump that pairs insulin with glucagon.

Why it matters

Beta Bionics is aiming to differentiate its insulin delivery products through a focus on automation, which it believes can drive broader adoption by making the technology more accessible to both patients and providers. The company's strategy highlights the industry's shift toward more autonomous insulin management systems, which could have significant implications for diabetes care.

The details

Beta Bionics' Chief Financial Officer Stephen Feider described the iLet pump as designed to adapt insulin delivery through a learning algorithm, allowing patients to start the system with just a few inputs. Feider said this approach reduces the setup and ongoing management burden for healthcare providers. He framed long-term success around offering both tubed and patch pump options, integrating with popular continuous glucose monitors, and enabling pharmacy-channel purchasing. Feider said the company ended 2025 with around 10% new patient market share, driven by both early adopters and patients who 'would not do well' on other pumps due to the level of engagement required. He cited three key barriers to broader adoption: patient preference for patch pumps, some patients' desire for more active management of pump settings, and the challenge of changing established behavior within endocrinology practices.

  • Beta Bionics ended 2025 with 63 sales territories.
  • The company plans to add at least 20 new territories in 2026, with most additions 'front-loaded' into the first half of the year.
  • Beta Bionics is targeting commercialization of its Mint patch pump 'by the end of 2027'.
  • The company plans two phase II trials for its bi-hormonal pump 'this year', followed by a phase III pivotal trial requiring at least a year of drug exposure.

The players

Beta Bionics

A clinical-stage medical device company headquartered in Boston, Massachusetts, focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions.

Stephen Feider

The Chief Financial Officer of Beta Bionics.

Got photos? Submit your photos here. ›

What they’re saying

“Patients can start the system by entering body weight and selecting 'Go,' after which the pump's learning algorithm adapts and delivers insulin. Patients are intended to announce meals, but Feider noted many do not, and he argued iLet is designed to accommodate varying levels of engagement.”

— Stephen Feider, Chief Financial Officer (MarketBeat)

“Adoption of automation-forward pumping will take time because 'doctors just don't change behavior overnight.' As validation of the direction of travel, Feider noted that other pump companies are now discussing more automated, learning-based systems that incorporate weight-based inputs similar in concept to iLet.”

— Stephen Feider, Chief Financial Officer (MarketBeat)

What’s next

Beta Bionics plans to conduct two phase II trials for its bi-hormonal pump this year, followed by a phase III pivotal trial requiring at least a year of drug exposure.

The takeaway

Beta Bionics is positioning its insulin delivery products, particularly the iLet pump, around an 'automation-forward' approach that aims to reduce the burden on both patients and healthcare providers. This strategy highlights the industry's shift toward more autonomous insulin management systems, which could have significant implications for the future of diabetes care.